BioMarin Acquires Amicus for $4.8 Billion to Enhance Rare Disease Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BMRN?
Source: PRnewswire
- Acquisition Completed: BioMarin has finalized its acquisition of Amicus Therapeutics for $14.50 per share, totaling approximately $4.8 billion, significantly enhancing BioMarin's market position in the rare disease sector.
- New Drugs Added: This acquisition adds Galafold® for Fabry disease and Pombiliti® + Opfolda® for Pompe disease to BioMarin's commercial portfolio, which is expected to generate new revenue streams and expand market coverage.
- Future Guidance: BioMarin plans to provide updated FY 2026 guidance during its first quarter earnings call, with expectations that this acquisition will drive future revenue growth and product line diversification.
- Strategic Importance: The CEO of BioMarin stated that this acquisition not only strengthens the company's growth strategy but also leverages its global scale and advanced manufacturing capabilities to further enhance treatment options for patients with rare diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMRN
Wall Street analysts forecast BMRN stock price to rise
19 Analyst Rating
14 Buy
5 Hold
0 Sell
Moderate Buy
Current: 53.180
Low
60.00
Averages
87.35
High
120.00
Current: 53.180
Low
60.00
Averages
87.35
High
120.00
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioMarin to Host Q1 2026 Financial Results Call on May 4
- Conference Call Announcement: BioMarin Pharmaceutical Inc. will host a conference call on May 4, 2026, at 4:30 p.m. ET, where CEO Alexander Hardy will discuss Q1 2026 financial results and provide a business update, which is expected to deliver crucial financial and strategic insights to investors.
- Dial-in Information Released: The call will feature a U.S./Canada dial-in number of 800-715-9871 and an international dial-in number of 646-307-1963, ensuring global investor participation and access to the latest company developments.
- Live Webcast Access: Interested parties can access a live audio webcast of the conference call via the investor section of BioMarin's website, enhancing transparency and fostering engagement with investors.
- Replay Service Offered: Following the call, BioMarin will provide a one-week replay service, allowing investors who could not participate live to access key information by dialing 800-770-2030 (U.S./Canada) or 609-800-9909 (international).
See More
BioMarin Acquires Amicus for $4.8 Billion to Enhance Rare Disease Portfolio
- Acquisition Completed: BioMarin has finalized its acquisition of Amicus Therapeutics for $14.50 per share, totaling approximately $4.8 billion, significantly enhancing BioMarin's market position in the rare disease sector.
- New Drugs Added: This acquisition adds Galafold® for Fabry disease and Pombiliti® + Opfolda® for Pompe disease to BioMarin's commercial portfolio, which is expected to generate new revenue streams and expand market coverage.
- Future Guidance: BioMarin plans to provide updated FY 2026 guidance during its first quarter earnings call, with expectations that this acquisition will drive future revenue growth and product line diversification.
- Strategic Importance: The CEO of BioMarin stated that this acquisition not only strengthens the company's growth strategy but also leverages its global scale and advanced manufacturing capabilities to further enhance treatment options for patients with rare diseases.
See More
Intellia's Gene Editing Therapy Trial Achieves Success
- Clinical Trial Success: Intellia Therapeutics' gene editing therapy achieved an 87% reduction in attacks during late-stage trials, significantly surpassing the placebo group, marking a crucial milestone in gene editing and paving the way for FDA approval.
- Positive Patient Outcomes: Six months post-treatment, 62% of patients were attack-free and not using other therapies, demonstrating the therapy's efficacy and durability, which could transform treatment paradigms for hereditary angioedema patients.
- Favorable Safety Profile: Despite a patient death in a separate trial due to liver toxicity, Intellia reported a favorable safety and tolerability profile for its therapy, with common side effects being infusion-related reactions, headaches, and fatigue, bolstering market confidence.
- Market Competition Outlook: If approved by the FDA, Intellia's lonvoguran ziclumeran will compete with other chronic drugs, and while the commercial success of gene therapies has been mixed, the potential for a one-time treatment continues to attract investor interest.
See More
BioMarin to Host Q1 2026 Financial Results Call on May 4
- Conference Call Announcement: BioMarin Pharmaceutical Inc. will host a conference call on May 4, 2026, at 4:30 p.m. ET, where CEO Alexander Hardy will discuss Q1 2026 financial results and provide a business update, which is expected to deliver crucial financial and strategic insights to investors.
- Dial-in Information Released: The call will feature dial-in numbers including 800-715-9871 for U.S./Canada and 646-307-1963 for international participants, ensuring global investors can easily join this significant financial communication, thereby enhancing transparency and investor confidence.
- Live Webcast Access: Interested parties can access a live audio webcast of the conference call via the investor section of BioMarin's website, further improving information accessibility and ensuring all stakeholders stay informed about the company's latest developments.
- Replay Service Offered: Following the call, BioMarin will provide a replay service for one week, with dial-in numbers of 800-770-2030 for U.S./Canada and 609-800-9909 for international, ensuring that investors who cannot participate live can still obtain key information, thus strengthening communication between the company and its investors.
See More
BioMarin Appoints New Board Chair Ian Clark
- Board Chair Transition: BioMarin Pharmaceutical Inc. announced the appointment of Ian Clark as Chair of the Board, with the election set for June 2 at the Annual Meeting, indicating a significant governance shift for the company.
- Experienced Leadership: Ian Clark, who joined BioMarin's board in 2025, previously served as CEO of Genentech from 2010 to 2016, bringing extensive biopharmaceutical industry experience that could benefit the company's future growth.
- Current Chair's Retirement: Current Chair Richard Meier will retire after nearly 20 years on the board, having joined in 2006 and served as Chair since 2023, signaling a new direction in the company's leadership.
- Stock Price Fluctuation: BioMarin's stock closed down 0.47% at $54.62 on Nasdaq, but traded up 1.24% in after-hours at $55.30, reflecting a relatively stable market reaction to the new chair appointment.
See More
BioMarin Appoints New Chair of the Board
- Board Leadership Change: BioMarin Pharmaceutical Inc. has appointed Ian T. Clark as Chair of the Board, succeeding Richard A. Meier, who has served for 20 years, marking a significant governance shift that is expected to drive further growth in the rare disease sector.
- New Chair Background: Ian T. Clark joined BioMarin's Board in 2025 and previously served as CEO of Genentech, bringing extensive governance and leadership experience in the biopharmaceutical industry, which is anticipated to provide strategic insights as the company expands in 80 countries worldwide.
- Former Chair Contributions: Richard A. Meier has been on the Board since 2006, during which time the company saw meaningful improvements in profitability, with significant growth in non-GAAP operating margins and earnings per share, highlighting his crucial role in the company's evolution.
- Future Outlook: Under the new leadership, BioMarin plans to continue executing its global strategy, leveraging recent acquisitions to unlock significant value for all stakeholders, particularly patients, showcasing the company's strong potential in the rare disease treatment landscape.
See More
BioMarin to Host Q1 2026 Financial Results Call on May 4
- Conference Call Announcement: BioMarin Pharmaceutical Inc. will host a conference call on May 4, 2026, at 4:30 p.m. ET, where CEO Alexander Hardy will discuss Q1 2026 financial results and provide a business update, which is expected to deliver crucial financial and strategic insights to investors.
- Dial-in Information Released: The call will feature a U.S./Canada dial-in number of 800-715-9871 and an international dial-in number of 646-307-1963, ensuring global investor participation and access to the latest company developments.
- Live Webcast Access: Interested parties can access a live audio webcast of the conference call via the investor section of BioMarin's website, enhancing transparency and fostering engagement with investors.
- Replay Service Offered: Following the call, BioMarin will provide a one-week replay service, allowing investors who could not participate live to access key information by dialing 800-770-2030 (U.S./Canada) or 609-800-9909 (international).
See More
BioMarin Acquires Amicus for $4.8 Billion to Enhance Rare Disease Portfolio
- Acquisition Completed: BioMarin has finalized its acquisition of Amicus Therapeutics for $14.50 per share, totaling approximately $4.8 billion, significantly enhancing BioMarin's market position in the rare disease sector.
- New Drugs Added: This acquisition adds Galafold® for Fabry disease and Pombiliti® + Opfolda® for Pompe disease to BioMarin's commercial portfolio, which is expected to generate new revenue streams and expand market coverage.
- Future Guidance: BioMarin plans to provide updated FY 2026 guidance during its first quarter earnings call, with expectations that this acquisition will drive future revenue growth and product line diversification.
- Strategic Importance: The CEO of BioMarin stated that this acquisition not only strengthens the company's growth strategy but also leverages its global scale and advanced manufacturing capabilities to further enhance treatment options for patients with rare diseases.
See More
Intellia's Gene Editing Therapy Trial Achieves Success
- Clinical Trial Success: Intellia Therapeutics' gene editing therapy achieved an 87% reduction in attacks during late-stage trials, significantly surpassing the placebo group, marking a crucial milestone in gene editing and paving the way for FDA approval.
- Positive Patient Outcomes: Six months post-treatment, 62% of patients were attack-free and not using other therapies, demonstrating the therapy's efficacy and durability, which could transform treatment paradigms for hereditary angioedema patients.
- Favorable Safety Profile: Despite a patient death in a separate trial due to liver toxicity, Intellia reported a favorable safety and tolerability profile for its therapy, with common side effects being infusion-related reactions, headaches, and fatigue, bolstering market confidence.
- Market Competition Outlook: If approved by the FDA, Intellia's lonvoguran ziclumeran will compete with other chronic drugs, and while the commercial success of gene therapies has been mixed, the potential for a one-time treatment continues to attract investor interest.
See More
BioMarin to Host Q1 2026 Financial Results Call on May 4
- Conference Call Announcement: BioMarin Pharmaceutical Inc. will host a conference call on May 4, 2026, at 4:30 p.m. ET, where CEO Alexander Hardy will discuss Q1 2026 financial results and provide a business update, which is expected to deliver crucial financial and strategic insights to investors.
- Dial-in Information Released: The call will feature dial-in numbers including 800-715-9871 for U.S./Canada and 646-307-1963 for international participants, ensuring global investors can easily join this significant financial communication, thereby enhancing transparency and investor confidence.
- Live Webcast Access: Interested parties can access a live audio webcast of the conference call via the investor section of BioMarin's website, further improving information accessibility and ensuring all stakeholders stay informed about the company's latest developments.
- Replay Service Offered: Following the call, BioMarin will provide a replay service for one week, with dial-in numbers of 800-770-2030 for U.S./Canada and 609-800-9909 for international, ensuring that investors who cannot participate live can still obtain key information, thus strengthening communication between the company and its investors.
See More
BioMarin Appoints New Board Chair Ian Clark
- Board Chair Transition: BioMarin Pharmaceutical Inc. announced the appointment of Ian Clark as Chair of the Board, with the election set for June 2 at the Annual Meeting, indicating a significant governance shift for the company.
- Experienced Leadership: Ian Clark, who joined BioMarin's board in 2025, previously served as CEO of Genentech from 2010 to 2016, bringing extensive biopharmaceutical industry experience that could benefit the company's future growth.
- Current Chair's Retirement: Current Chair Richard Meier will retire after nearly 20 years on the board, having joined in 2006 and served as Chair since 2023, signaling a new direction in the company's leadership.
- Stock Price Fluctuation: BioMarin's stock closed down 0.47% at $54.62 on Nasdaq, but traded up 1.24% in after-hours at $55.30, reflecting a relatively stable market reaction to the new chair appointment.
See More
BioMarin Appoints New Chair of the Board
- Board Leadership Change: BioMarin Pharmaceutical Inc. has appointed Ian T. Clark as Chair of the Board, succeeding Richard A. Meier, who has served for 20 years, marking a significant governance shift that is expected to drive further growth in the rare disease sector.
- New Chair Background: Ian T. Clark joined BioMarin's Board in 2025 and previously served as CEO of Genentech, bringing extensive governance and leadership experience in the biopharmaceutical industry, which is anticipated to provide strategic insights as the company expands in 80 countries worldwide.
- Former Chair Contributions: Richard A. Meier has been on the Board since 2006, during which time the company saw meaningful improvements in profitability, with significant growth in non-GAAP operating margins and earnings per share, highlighting his crucial role in the company's evolution.
- Future Outlook: Under the new leadership, BioMarin plans to continue executing its global strategy, leveraging recent acquisitions to unlock significant value for all stakeholders, particularly patients, showcasing the company's strong potential in the rare disease treatment landscape.
See More
